The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
Zydus Lifesciences and SBL have mutually decided to extend the date of closing upto March 31, 2025
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Subscribe To Our Newsletter & Stay Updated
